1. Bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway.
- Author
-
Zhu Z, Liang S, Hong Y, Qi Y, Sun Q, Zhu X, Wei Y, Xu Y, and Chen Q
- Subjects
- Humans, Cell Line, Tumor, Animals, Cell Proliferation drug effects, Mice, Brain Neoplasms drug therapy, Brain Neoplasms metabolism, Brain Neoplasms pathology, Epithelial-Mesenchymal Transition drug effects, Glioblastoma drug therapy, Glioblastoma metabolism, Glioblastoma pathology, Apoptosis drug effects, Mitochondria drug effects, Mitochondria metabolism, Proto-Oncogene Proteins c-akt metabolism, Signal Transduction drug effects, Bufanolides pharmacology, Bufanolides therapeutic use, Reactive Oxygen Species metabolism
- Abstract
Glioblastoma multiforme (GBM) is the most prevalent and lethal primary intracranial neoplasm in the adult population, with treatments of limited efficacy. Recently, bufotalin has been shown to have anti-cancer activity in a variety of cancers. This investigation aims to investigate the effect of bufotalin on GBM and elucidate its potential underlying mechanism. Our results show that bufotalin not only inhibits the proliferation and epithelial-mesenchymal transition (EMT) but also triggers apoptosis in GBM cells. The result of RNA-seq indicated that bufotalin could induce mitochondrial dysfunction. Moreover, our observations indicate that bufotalin induces an excessive accumulation of intracellular reactive oxygen species (ROS) in GBM cells, leading to mitochondrial dysfunction and the dephosphorylation of AKT. Moreover, bufotalin improved TMZ sensitivity of GBM cells in vitro and in vivo . In conclusion, bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway.
- Published
- 2024
- Full Text
- View/download PDF